Monte Rosa Therapeutics, Inc.
HealthcareNASDAQ:GLUE · NASDAQ Global Select
+$1.14 today
Vol 1.08M · Avg 1.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-16.6%
avg -6.6%
ROIC
-13.6%
avg -56.9%
ROA
-8.6%
avg -38.1%
Analysis
ROA is currently the strongest return metric at -8.6% versus its period average of -38.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Markus Warmuth | President, Chief Executive Officer & Director | $1.08M | — | 55 | $594,538.00 | 0.91% |
Filip Janku | Chief Medical Officer | $833,600.00 | — | 52 | $65,837.00 | 0.10% |
Phil Nickson | Chief Business & Legal Officer | $833,600.00 | — | 47 | $55,000.00 | 0.08% |
Sharon Townson | Chief Scientific Officer | $644,600.00 | — | 51 | $73,845.00 | 0.11% |
John C. Castle | Chief Data & Information Officer | — | — | 55 | $78,500.00 | 0.12% |
Andrew Funderburk | Chief Investor Relations and Strategy Officer | — | — | — | $25,800.00 | 0.04% |
Magnus Walter DPHIL | Chief Technology Officer | — | — | — | — | — |
Matthew Bowen | Corporate Controller & Principal Accounting Officer | — | — | 37 | $19,500.00 | 0.03% |
Jennifer Champoux | Chief Operating Officer | — | — | 54 | $62,371.00 | 0.10% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
23
$2.06M
Net Sentiment
$2.06M
Net selling
Most Active
Warmuth Markus
9 transactions
1–10 of 23
Analysis
Insiders reported 0 buys worth $0.00 and 23 sells worth $2.06M over the last 12 months. That adds up to net selling of $2.06M. Warmuth Markus was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Theravance Biopharma, Inc.
NASDAQ:TBPH
$857.84M
Geron Corporation
NASDAQ:GERN
$737.75M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Valneva SE
NASDAQ:VALN
$507.78M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
Who manages GLUE?
Monte Rosa Therapeutics, Inc. (GLUE) lists 9 active executives. The top listed executive is John C. Castle, Chief Data & Information Officer.
Are GLUE insiders buying or selling?
Recent insider activity shows net buying of $99.27M.
Explore More
Continue the stock analysis
Jump to another research area for this company.